OWL: OCOSH Classification/Orthopaedic Oncology/Connective and Soft Tissue Neoplasms/Bone Neoplasms/Plasmacytoma/Multiple Myeloma

Bisphosphonates Are Essential Component of Multiple Myeloma Treatment Medscape CME

Not Available — 2009-09-28 18:07:38 GMT

Upon completion of this activity, participants will be able to:
List risk factors for multiple myeloma.
Describe recommendations for treatment with bisphosphonates for patients with multiple myeloma.
Medscape Medical News CME � 2009

Multiple Myeloma and Other Plasma Cell Neoplasms PDQ

Not Available — 2007-07-10 18:07:38 GMT

Multiple Myeloma and Other Plasma Cell Neoplasms (PDQ�): Treatment
Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 to 30 months and a 10-year survival of 3%.

multiple myeloma CHORUS

Brian Funaki, MD — 2002-01-31 18:07:38 GMT

* most common primary malignant neoplasm of bone
* 50-70y; M:F 2:1
* symptoms: vague bone pain of progressive severity, fever, anemic sxs
* complications: pathologic fractures
* solitary plasmacytoma: solitary osseous focus of MM (uncommon)
x-ray findings:
* loss of bone density - from diffuse marrow involvement
* "punched out" lesions - esp. skull, long bones
* diffuse bone destruction - esp. pelvis, sacrum
* invasion of soft tissues - often paraspinal, extrapleural mass
* osteosclerosis - very rare
* metastatic calcifications - particularly kidneys, occ. lungs
NB: does not involve pedicles of spine

multiple myeloma LSBU

IDM — 2002-01-31 18:07:38 GMT

Radiology case 418-3452 Female patient aged 50 years with backache and proteinuria. Recent pain in right humerus after a fall.
There are lytic areas in the metaphysis and diaphysis of the right humerus. Similar distributed lytic areas are present in the clavicle, scapula and ribs. The lytic lesions are predominantly in a medullary location and undermine the bone cortex from below, cortical scalloping. There is a fracture crossing the proximal metaphysis of the right humerus.

Multiple myeloma LSBU

IDM — 2002-01-31 18:07:38 GMT

Radiology case 48--3452 Clinical presentation: 42 year old male with an 8 month history of increasing back pain. Had been bed-ridden for the last 3 weeks. The serum calcium was markedly elevated.
The plain film view of the pelvis shows extensive patchy bone destruction. The lytic areas undermine the cortex at various points, but the cortex is intact with no visible lamellar reaction.
There is extensive patchy osteoporosis of the lumbar vertebrae and visible destructive collapse of the second lumbar vertebra, having a concave upper margin in the lateraL view. Its pedicles are relatively intact.
The bone scan shows uptake in the anterior ends of right 3-5th ribs and left 5 and 6th ribs. The lumbar spine uptake is patchy and totally inconsistent with the extent of bone destruction in the plain films. The patient is young for this condition, but this appearance is typical of the pathology.

Multiple Myeloma POEMS Syndrome TumorLibrary

James Johnston — 2010-06-07 18:07:38 GMT

Illustrated case

Multiple Myeloma SA Registrars Notebook

Not Available — 2007-07-06 18:07:38 GMT

Incidence, Clinical, Xrays, Investigation, Pathology, Treatment, Prognosis

Multiple Myeloma TumorLibrary

James Johnston — 2010-06-07 18:07:38 GMT

Illustrated cases. See also on this site - Multiple myeloma pseudotumor (Fibrogenesis imperfecta ossium)

Multiple Myeloma Wheeless

Wheeless — 2007-03-28 18:07:38 GMT

Discussion: - myeloma is malignant tumor of plasma cells arising from a single clone; - multiple myeloma accounts for > 40% of primary malignant tumors of bone. - it is most common malignant primary tumor of bone - may arise as single intraosseous tumor but more often it develops as multiple painful lesions throughout skeleton (multiple myeloma); - whether from single or multiple sites, myeloma spreads to involve virtually entire bone marrow which eventually produces death

Multiple Myeloma Wikibooks

Collaborative — 2006-12-02 18:07:38 GMT

Multiple Myeloma is a neoplasm of differentiated plasma cells resulting from malignant clonal expansion and overproduction of monoclonal immunoglobulins. Common complications include recurrent bacterial infections, anemia, osteolytic lesions and renal insufficiency. Diagnostic Radiology/Musculoskeletal Imaging/Tumors Basic/Multiple Myeloma From Wikibooks, the open-content textbooks collection

Multiple Myeoloma Pelvis

Mike Tobin — 2006-12-17 18:07:38 GMT

destruction is widespread and obvious. Close inspection Multiple Myeloma of the largest lesion shows it to be purely lytic, without any matrix or calcification. There are numerous "tear-drop" shaped lytic lesions in the Multiple Myeloma left femur. Pathologic fracture of the neck of the femur can be clearly seen.
For all practical purposes, the differential diagnosis is between Multiple Myeloma (MM) and metastatic disease, especially breast in a female. While one cannot usually decide between MM and lytic metastases

Myeloma eMedicine Orthopedics

Seema S Rizvi, MD & Howard A Chansky, MD — 2008-04-07 18:07:38 GMT

Multiple myeloma (MM) is characterized by neoplastic proliferation of plasma cells involving more than 10% of the bone marrow. The disease results in the production of monoclonal immunoglobulins, which may be identified with serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP). Plasma-cell proliferation causes extensive skeletal destruction with osteolytic lesions, anemia, and hypercalcemia. Excessive production of M proteins can lead to renal failure, hyperviscosity, and recurrent infections. MM accounts for 10% of all hematologic cancers.
Synonyms and related keywords: multiple myeloma, MM, plasma cell dyscrasia, plasma cell proliferation, hematologic cancer, plasmacytoid lymphocytes, M proteins, plasmacytoma
Seema S Rizvi, MD & Howard A Chansky, MD 2005

Myeloma Pretest and Tutorial

Frassica & Sims — 2007-03-27 18:07:38 GMT

Orthopedics Hyperguide

Pathogenesis and Management of Myeloma Bone Disease

Dimitrios Christoulas; Evangelos Terpos; Meletios A Dimopoulos — 2009-09-30 18:07:38 GMT

Osteolytic bone disease is a frequent complication of multiple myeloma, resulting in skeletal complications that are a significant cause of morbidity and mortality. It is the result of increased activity of osteoclasts that is not followed by reactive bone formation by osteoblasts. Recent studies have revealed novel molecules and pathways that are implicated in osteoclast activation and osteoblast inhibition, including the RANKL/osteoprotegerin pathway, macrophage inflammatory proteins and the wingless type signaling pathway. These molecules also appear to interfere with tumor growth and survival, providing possible targets for the development of novel drugs for the management of lytic disease in myeloma. Currently, bisphosphonates are the mainstay of treatment for myeloma bone disease, although several novel agents appear promising. This review focuses on recent advances in understanding the biology of bone disease in multiple myeloma, diagnosis and recent progress in treatment options.
Dimitrios Christoulas; Evangelos Terpos; Meletios A Dimopoulos Expert Rev Hematol. 2009;2(4):385-398 Full Text

Radiology Cases Myeloma Plasmacytoma LSBU

IDM — 2009-07-29 18:07:38 GMT

Plasmacytoma amd multiple myeloma are both patterns of bone destruction, produced by an accumulation of plasma cells. The disease occurs in late middle age with a peak incidence at 60 years. Males are more likely to be affected, 2:1. The single mass of plasmacytoma is lytic and expands the bone with thinning of the cortex. The Multiple myeloma is multifocal and primarily medullary, in the bone marrow. There may be cortical erosion or scalloping.
Since the Isotope bone scan does not record an abnormality, unless a reaction to a fracture, plain film surveys remain one way of assessing disease. The biochemistry reveals an accumulation of protein precursors to antibody production, the para-proteins. The accurate indicator of poor prognosis is impairment of renal function.